Evaluating Ingevity (NGVT) After Recent Share Price Volatility And A 21.7% Undervaluation Claim

Ingevity Corporation

Ingevity Corporation

NGVT

0.00

What the latest move in Ingevity (NGVT) means for investors

Ingevity (NGVT) has been drawing attention after recent trading, with the stock closing at $66.93 and showing mixed short term performance, including a move down of about 12% over the past month.

Recent trading has been choppy, with a 1-day share price return of 1.42% and a 30-day share price return down 11.5%. However, year to date the share price return is 11.38% and the 1-year total shareholder return is 54.5%, suggesting earlier momentum has cooled in the short term.

If this move in Ingevity has you thinking about where else capital could work hard, it may be worth scanning 34 power grid technology and infrastructure stocks

With the stock trading at $66.93, alongside an indicated discount to both analyst targets and one intrinsic value estimate, the key question for you is simple: is Ingevity still undervalued or is the market already pricing in its future growth?

Most Popular Narrative: 21.7% Undervalued

On the widely followed narrative, Ingevity's fair value of $85.50 sits well above the last close at $66.93, putting the focus firmly on whether the underlying business story justifies that gap.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Want to see what has to happen for that higher fair value to hold up? The narrative leans on sharper margins, a reshaped portfolio and a very specific earnings trajectory.

Result: Fair Value of $85.50 (UNDERVALUED)

However, this depends on assumptions that could change, including prolonged weakness in key industrial and automotive markets and pressure on Advanced Polymer Technologies margins after the goodwill impairment.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another way to look at valuation

The earlier fair value narrative leans heavily on future earnings and cash flows. Yet on simple sales based pricing Ingevity looks expensive. The stock trades on a P/S of about 2x, compared with roughly 1.2x for peers, 1.1x for the wider US Chemicals group, and a fair ratio of 1.4x. That pricing gap points to less margin for error if the upbeat story on margins and buybacks does not fully play out, so how comfortable are you paying a premium for a business that is still loss making today?

NYSE:NGVT P/S Ratio as at Jun 2026
NYSE:NGVT P/S Ratio as at Jun 2026

Next Steps

With mixed signals on valuation and sentiment, this is a moment to look closely at the numbers, weigh both the cautious and optimistic angles, and move quickly to frame your own view using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop at one stock, you risk missing stronger opportunities. Broaden your watchlist now and let the best ideas come to you first.

  • Target potential mispricings by scanning 47 high quality undervalued stocks that combine quality fundamentals with market apathy.
  • Strengthen your income stream by reviewing 10 dividend fortresses built around higher yields and resilient payouts.
  • Prioritize resilience by focusing on 62 resilient stocks with low risk scores that score well on stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.